KPKatarzyna Pastusiak

Katarzyna Pastusiak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Katarzyna Pastusiak has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Planetary diet in the prevention of carbohydrate metabolism disorders

    by Anna Maria Mieczyńska, Katarzyna Magdalena Pastusiak-Zgolińska

    Introduction and objective: Carbohydrate metabolism disorders are among the most severe health problems worldwide and, therefore, solutions that improve their prevention are constantly being sought. An appropriate diet, such as the planetary health diet the assumptions of which are similar to...

  • Open Access

    Can Adipokine FAM19A5 Be a Biomarker of Metabolic Disorders?

    by Agnieszka Wesołek-Leszczyńska, Katarzyna Pastusiak, Paweł Bogdański, Monika Szulińska

    Aim: One of the most critical functions of adipose tissue is the production of adipokines, ie, numerous active substances that regulate metabolism. One is the newly discovered FAM19A5, whose older name is TAFA-5. Purpose: The study aimed to review the literature on the FAM19A5 protein. Methods: The review was conducted in December 2023 using the PubMed (Medline) search engine. Sixty-four papers were included in the review. Results: This protein exhibits the characteristics of an adipokine with positive features for maintaining homeostasis. The results showed that FAM19A5 was highly expressed in adipose tissue, with mild to moderate expression in the brain and ovary. FAM19A5 may also inhibit vascular smooth muscle cell proliferation and migration through the perivascular adipose tissue paracrine pathway. Serum levels of FAM19A5 were decreased in obese children compared with healthy controls. There are negative correlations between FAM19A5, body mass index, and fasting insulin. Serum FAM19A5 level is correlated with type 2 diabetes, waist circumference, waist-to-hip ratio, glutamic pyruvic transferase, fasting plasma glucose, HbA1c, and mean shoulder pulse wave velocity. FAM19A5 expression was reduced in mice with obesity. However, the data available needs to be clarified or contradictory. Conclusion: Considering today’s knowledge about FAM19A5, we cannot consider this protein as a biomarker of the metabolic syndrome. According to current knowledge, FAM19A5 cannot be considered a marker of metabolic disorders because the results of studies conducted in this area are unclear.


  • Open Access

    MALDI-TOF MS Characterisation of the Serum Proteomic Profile in Insulin-Resistant Normal-Weight Individuals

    by Katarzyna Pastusiak, Eliza Matuszewska, Dagmara Pietkiewicz, Jan Matysiak, Pawel Bogdanski

    Insulin resistance (IR) is one of the most common metabolic disorders worldwide and is involved in the development of diseases, such as diabetes and cardiovascular diseases, affecting civilisations. The possibility of understanding the molecular mechanism and searching for new biomarkers useful in assessing IR can be achieved through modern research techniques such as proteomics. This study assessed the protein–peptide profile among normal-weight patients with IR to understand the mechanisms and to define new risk biomarkers. The research involved 21 IR and 43 healthy, normal-weight individuals, aged 19–65. Serum proteomic patterns were obtained using matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry. The proposed methodology identified six proteins differentiating normal weight IR and insulin sensitive individuals. They were fibrinogen alpha chain, serum albumin, kininogen-1, complement C3, serotransferrin, and Ig gamma-1 chain, which could potentially be related to inflammation. However, further investigation is required to confirm their correlation with IR.


  • RESISTIN IS NOT A USEFUL INSULIN RESISTANCE MARKER FOR NON-OBESE PATIENTS

    by K. Pastusiak, M. Kregielska-Narozna, P. Bogdanski

    Resistin, an adipokine produced in fat tissue, may be linked to insulin resistance (IR) and type 2 diabetes. Previous data are controversial and have focused mainly on obese patients. We aimed to evaluate whether resistin plays a role in the development of IR in normal-weight individuals. The study involved 77 normal-weight participants. We defined IR using different indexes and cut-off points. Resistin, fasting insulin, glucose, and lipids concentrations and anthropometric parameters were measured. Serum resistin concentration was not associated with IR. Resistin concentration was weakly related to age in all insulin-sensitive groups and low-density lipoprotein cholesterol concentration in all IR groups. Moreover, a weak negative correlation between high-density lipoprotein cholesterol and resistin concentrations was observed in the IR group categorised by the 1.69 cut-off of the homeostasis model assessment of IR. The data suggest that resistin is not a useful marker for the prediction of IR in normal-weight individuals.